| Full Name |
SARS-Associated Coronavirus Nucleocapsid (1-49/192-220)
|
Abbreviated Name-1 |
SARS-CoV nucleocapsid; SARS-CoV N; |
| Documents |
|---|
| Figures |
|---|
| Reference |
|---|
Chunling M, et al. Enhanced Induction of SARS-CoV Nucleocapsid Protein-Specific Immune Response Using DNA Vaccination followed by Adenovirus Boosting in BALB/c Mice. Intervirology. Jun 2006; 49(5): 307-318.
Shi SQ, et al. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Mol. Immunol. Apr 2006; 43(11): 1791-1798.
|
|
Description |
E. coli derived recombinant. The protein contains Nucleocapsid protein immunodominant regions. The SARS-CoV nucleocapsid (N) protein is a 423 amino-acid, predicted phospho-protein of 46,000 Da that shares little homology with other members of the coronavirus family. A short serine-rich stretch, and a putative bipartite nuclear localization signal are unique to it, thus suggesting its involvement in many important functions during the viral life cycle.
|
M.W. |
46,000 Da |
Purity |
Protein is >95% pure as determined by 10% PAGE (coomassie staining). |
Storage |
Protein is shipped at ambient temperature. Upon arrival, store at -20°C. |
Concentration |
1 mg/ml in 50 mM Tris-HCl, 60 mM NaCl, 50% glycerol. |
Stability |
Five year frozen, 6 month at +4°C. |
Specificity |
Immunoreactive with sera of SARS-infected individuals. |
Applications |
Antigen in ELISA and Western blots, excellent antigen for detection of SARS with minimal specificity problems. |
Note |
; |
